The progestogen-only implant is a long-acting reversible method of contraception (LARC).
The primary mode of action is to prevent ovulation. The first contraceptive implant
available in 1999 in the UK was Implanon which was a single, non-biodegradable, subdermal
rod licensed for up to 3 years of use. In 2010 this was replaced by Nexplanon which
has barium sulphate added to enable detection by X-ray. This implant contains 68 mg of the progestogen etonogestrel (ENG) and has a release rate of approximately 60–70 μg/day in weeks 5–6 decreasing to approximately 25–30 μg/day at the end of the third year [
[1]
]. It is registered in other countries worldwide including Australia and USA. In New
Zealand Jadelle, a two-rod levonorgestrel (LNG) containing implant is available and
is licensed to provide contraceptive protection for 5 years. Jadelle consists of two
rods containing a total of 150 mg LNG which provides low progestogen doses; 40 μg/day/day at 1 year of use, decreasing to about 30 μg/day from 24 months till the fifth year [
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Faculty of Sexual & Reproductive Health Care Clinical Guidance.: Progestogen-only Implants.2014 (https://www.fsrh.org/standards-and-guidance/documents/cec-ceu-guidance- implants-feb-2014/ [Accessed 3 March, 2017])
- Jadelle (levonorgestrel Implants) for Subdermal Use.2017 (http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020544s010lbl.pdf (Accessed March 3, 2017))
- Long-acting Reversible Contraception: The Effective and Appropriate Use of Long-acting Reversible Contraception.2005 (http://guidance.nice.org.uk/CG30 [Accessed 3 March, 2017)])
- Contraceptive efficacy.in: Hatcher R. Trussell J. Nelson A.L. Cates W. Kowal D. Policar M. Contraceptive Technology. 20th Revised Edition). Ardent Media, New York, NY2011: 779-863
- Implantable contraceptives for women:effectiveness, discontinuation rates, return of fertility and outcomes of pregnancies.Contraception. 2002; 65: 29-37
- Issues in Abortion, Pregnancy and Birth. 29 May 2011.2011 (http://www.reproductivereview.org/index.php/rr/article/971/ (Accessed 3 March 2017))
- Faculty of Sexual & Reproductive Health Care Clinical Guidance: Contraception for Women over 40.2010 (https://www.fsrh.org/standards-and-guidance/documents/cec-ceu-guidance-womenover40-jul-2010/ [Accessed 3 March, 2017])
- Choosing a contraceptive: efficacy, safety, and personal considerations.in: Hatcher R.A. Trussell J. Nelson A.L. Cates W. Kowal D. Policar M. Contraceptive Technology. Twentieth Revised edition. Ardent media, New York NY2011: 45-74
- UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2016).2016 (https://www.fsrh.org/standards-and-guidance/external/ukmec-2016-digital-version/ (Accessed 3 March 2017))
- Hormonal contraceptives for contraception in overweight or obese women.Cochrane Database Syst. Rev. 2016; 8 (Art. No.: CD008452)https://doi.org/10.1002/14651858.CD008452.pub
- Hormone therapy in postmenopausal women and risk of endometrial hyperplasia: a cochrane review summary.Maturitas. 2014; 77: 4-6
- Boiavailability and bioequivalence from two oral formulations of desogestrel: Cerazette and Liseta.Eur. J. Drug Metab. Pharmacokinet. 1999; 24: 335-343
- for the WHO study group on subdermal contraceptive implants for women. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.Hum. Reprod. 2016; 31: 2491-2498
- New developments in long-acting reversible contraception: the promise of intrauterine devices and implants to improve family planning services.Fertil. Steril. 2016; 106: 1273-1281
Article info
Publication history
Published online: March 24, 2017
Accepted:
March 22,
2017
Received:
March 18,
2017
Identification
Copyright
© 2017 Elsevier B.V. All rights reserved.
